Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 8/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 7/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237295 | 0.84 | SIRT6 (0.68) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL22634636 | 0.84 | SIRT6 (0.68) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL16284338 | 0.84 | SIRT6 (0.68) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL3550715 | 0.83 | SIRT6 (0.57) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL27661509 | 0.82 | SIRT6 (0.64) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL13312473 | 0.81 | SIRT6 (0.73) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL3546618 | 0.80 | MAPT (0.55) | SIRT6MAPTMAPK1ALDH1A1HTR6 | |
| SCHEMBL22634679 | 0.80 | SIRT6 (0.66) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL10061481 | 0.80 | MAPT (0.66) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 | |
| SCHEMBL28764740 | 0.79 | SIRT6 (0.57) | SIRT6MAPTMAPK1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1747216-B1 | SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2014-01-08 | — | — | EP | disclosed |
| CN-1950360-B | Substituted pyrrole-2, 5-diones as protein kinase c inhibitors | NOVARTIS AG | 2011-07-20 | — | — | CN | disclosed |
| US-7851475-B2 | Substituted pyrrole-2, 5-diones as protein kinase C inhibitors | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| US-20090221605-A1 | SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2009-09-03 | — | — | US | disclosed |
| CN-1950360-A | Substituted pyrrole-2, 5-diones as protein kinase c inhibitors | NOVARTIS AG (CH) | 2007-04-18 | — | — | CN | disclosed |
| EP-1747216-A1 | SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS | Novartis Pharma AG. (CH) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005113545-A1 | SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS | NOVARTIS AG (CH) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221605-A1 | SUBSTITUTED PYRROLE-2, 5-DIONES AS PROTEIN KINASE C INHIBITORS | PRKCA, PRKCB, PRKCE | SIRT6 3346/4885MAPT 3711/4885MAPK1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.